Vol. 4 No. 7 (2024)
Reimbursement Reviews

Drospirenone (Slynd)

decorative image of the issue cover

Published July 25, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses drospirenone (Slynd), 4 mg tablet; oral administration.
  • Indication: For conception control in adolescent and adult females.